|Systematic (IUPAC) name|
|Trade names||Fanatrex, Gabarone, Gralise, Neurontin, Nupentin, Neogab|
|Licence data||US Daily Med:|
|Pregnancy cat.||B1 (AU) C (US)|
|Legal status||Prescription Only (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US)|
|Bioavailability||27-60% (inversely proportional to dose; a high fat meal also increases bioavailability)|
|Protein binding||Less than 3%|
|Metabolism||Not significantly metabolised|
|Half-life||5 to 7 hours|
|PDB ligand ID||GBN (, )|
|Mol. mass||171.237 g/mol|
|(what is this?)|
Gabapentin (Neurontin) is an anticonvulsant and analgesic drug. It was originally developed to treat epilepsy, and is currently also used to relieve neuropathic pain. It is recommended as a first line agent for the treatment of neuropathic pain arising from diabetic neuropathy, post-herpetic neuralgia, and central neuropathic pain.
Gabapentin is also commonly prescribed for many off-label uses, such as treatment of restless leg syndrome, anxiety disorders, insomnia, and bipolar disorder. There are, however, concerns regarding the quality of the trials conducted and evidence for some such uses, especially in the case of its use as a mood stabilizer in bipolar disorder.
- 1 Medical uses
- 2 Adverse effects
- 3 Pharmacology
- 4 Mechanism of action
- 5 Society and culture
- 6 Veterinary use
- 7 Synthesis
- 8 See also
- 9 References
- 10 External links
Gabapentin is used primarily to treat seizures and neuropathic pain. There are, however, concerns regarding the quality of the research on its use to treat migraines, bipolar disorder, and pain.
Gabapentin appears to provide pain relief for slightly more than 10% of people who take it for fibromyalgia or chronic neuropathic pain; however, the evidence for this conclusion is not very good. With respect to neuropathic pain there is greater evidence in postherpetic neuralgia and diabetic neuropathy and little evidence for other types of pain. There are side effects in nearly two thirds of people. It may reduce opioid use following surgery. There, however, is not evidence that it prevents chronic pain after surgery.
It may be helpful in neuropathic pain due to cancer. It has not been shown useful for HIV-associated sensory neuropathy. When used for neuropathic pain it does not appear superior to carbamazepine. It appears as effective as pregabalin and costs less. It does not appear to provide benefit for complex regional pain syndrome or to be useful for migraine prevention.
Gabapentin is approved for treatment of focal seizures in a number of countries and evidence supports its use for treating partial and mixed seizure disorders however there is insufficient evidence for its use in generalized epilepsy.
A variety of research has supported the use of gabapentin in the treatment of certain anxiety disorders. Evidence exists for its effectiveness in the treatment of social anxiety disorder and panic disorder. In addition, pregabalin, an analog of gabapentin with the same mechanism of action, has demonstrated effectiveness in the treatment of social anxiety disorder and generalized anxiety disorder, and is an approved treatment for the latter. Gabapentin is likely similarly effective for these conditions, and has the advantage of being significantly less expensive in comparison. Indeed, it is frequently prescribed off-label as a treatment for generalized anxiety disorder.
Gabapentin may help with certain menopausal symptoms, such as hot flashes. It may be effective in reducing pain and spasticity in multiple sclerosis. Gabapentin may reduce symptoms of alcohol withdrawal but it does not prevent the seizures often associated with this condition. Use for smoking cessation has had mixed results. Gabapentin helps with itching (pruritus) associated with renal failure (uremic pruritus) and other conditions.
Other off-label uses of gabapentin include treatment of, in addition to anxiety disorders, various other psychiatric disorders. However, the evidence for its use in many of these conditions has not been demonstrated. Numerous trials show that it is not effective alone as a mood-stabilizing treatment for bipolar disorder. It may be useful in the treatment of comorbid anxiety in bipolar patients, however. There is also insufficient evidence to support the use of gabapentin in disorders such as obsessive-compulsive disorder and treatment-resistant depression. However, it is well-established in the treatment of restless leg syndrome, which a prodrug form, gabapentin enacarbil, is indicated for. In addition, there is data in support of the effectiveness of gabapentin as a therapy for insomnia.
The most common side effects of gabapentin in adult patients include dizziness, fatigue, drowsiness, weight gain, and peripheral edema (swelling of extremities). Gabapentin may also produce sexual dysfunction in some patients, symptoms of which may include loss of libido, inability to reach orgasm, and erectile dysfunction. In children three to twelve years of age, researchers observed susceptibility to mild-to-moderate mood swings, hostility, concentration problems, and hyperactivity. Though rare, the literature reports several cases of hepatotoxicity. Gabapentin should be used carefully in patients with renal impairment due to possible accumulation and toxicity.
An increase in formation of adenocarcinomas was observed in rats during preclinical trials; however, the clinical significance of these results remains undetermined. Gabapentin is also known to induce pancreatic acinar cell carcinomas in rats through an unknown mechanism, perhaps by stimulation of DNA synthesis; these tumors did not affect the lifespan of the rats and did not metastasize.
May cause adverse effects to patient decision making ability.
In 2009 the U.S. Food and Drug Administration issued a warning of an increased risk of depression and suicidal thoughts and behaviors in patients taking gabapentin, along with other anticonvulsant drugs modifying the packaging insert to reflect this. In July 2009 the manufacturer of gabapentin (Pfizer) went to trial regarding the association between gabapentin and the increased risk of suicide.
Persons who accidentally or intentionally ingested overdoses have manifested drowsiness, sedation, blurred vision, slurred speech and somnolence or coma. Serum gabapentin concentrations may be measured to confirm diagnosis.
Some of its activity may involve interaction with voltage-gated calcium channels. Gabapentin binds to the α2δ subunit (1 and 2) and has been found to reduce calcium currents after chronic but not acute application via an effect on trafficking of voltage-dependent calcium channels in the central nervous system. Another possible mechanism of action, reported by Ben Barres and colleagues in Cell in 2009, is that gabapentin halts the formation of new synapses.
Mechanism of action
Gabapentin interacts with voltage-sensitive calcium channels in cortical neurons. Gabapentin increases the synaptic concentration of GABA, enhances GABA responses at non-synaptic sites in neuronal tissues, and reduces the release of mono-amine neurotransmitters. One of the mechanisms implicated in this effect of gabapentin is the reduction of the axon excitability measured as an amplitude change of the presynaptic fibre volley (FV) in the CA1 area of the hippocampus. This is mediated through its binding to presynaptic NMDA receptors. Other studies have shown that the antihyperalgesic and antiallodynic effects of gabapentin are mediated by the descending noradrenergic system, resulting in the activation of spinal alpha-2 adrenergic receptors. Gabapentin has also been shown to bind and activate the adenosine A1 receptor.
Society and culture
In December 2004 the FDA granted final approval to a generic equivalent to Neurontin made by the Israeli firm Teva.
Neurontin began as one of Pfizer's best selling drugs; however, Pfizer has come under heavy criticism and serious litigation for its marketing of the drug. They face allegations that, behind the scenes, Parke-Davis marketed the drug for at least a dozen supposed uses that the FDA had not approved. Today it is a mainstay drug for migraines, even though it was not approved for such use in 2004.
Gabapentin was originally approved by the U.S. Food and Drug Administration (FDA) in December 1993, for use as an adjuvant medication to control partial seizures (effective when added to other antiseizure drugs) in adults; that indication was extended to children in 2000. In 2004, its use for treating postherpetic neuralgia (neuropathic pain following shingles) was approved.
Although some small, non-controlled studies in the 1990s—mostly sponsored by gabapentin's manufacturer—suggested that gabapentin treatment for bipolar disorder may be promising, the preponderance of evidence suggests that it is not effective. Subsequent to the corporate acquisition of the original patent holder, the pharmaceutical company Pfizer admitted that there had been violations of FDA guidelines regarding the promotion of unproven off-label uses for gabapentin in the Franklin v. Pfizer case.
Reuters reported on March 25, 2010, that "Pfizer Inc violated federal racketeering law by improperly promoting the epilepsy drug Neurontin ... Under federal RICO law the penalty is automatically tripled, so the finding will cost Pfizer $141 million." The case stems from a claim from Kaiser Foundation Health Plan Inc. that "it was misled into believing Neurontin was effective for off-label treatment of migraines, bipolar disorder and other conditions. Pfizer argued that Kaiser physicians still recommend the drug for those uses."
Bloomberg News (3/26/10, Van Voris, Lawrence) added that "during the trial, Pfizer argued that Kaiser doctors continued to prescribe the drug even after the health insurer sued Pfizer in 2005. The insurer's website also still lists Neurontin as a drug for neuropathic pain, Pfizer lawyers said in closing argument."
The Wall Street Journal (3/26/10, Kamp) noted that Pfizer spokesman Christopher Loder said, "We are disappointed with the verdict and will pursue post-trial motions and an appeal." He would later add that "the verdict and the judge's rulings are not consistent with the facts and the law."
Franklin v. Pfizer case
While off-label prescriptions are common for a number of drugs and are legal, marketing of off-label uses of a drug is illegal. In 2004, Warner-Lambert agreed to plead guilty and pay $430 million in fines to settle civil and criminal charges regarding the illegal marketing of Neurontin for off-label purposes, and further legal action is pending. The 2004 settlement was one of the largest in U.S. history, and the first off-label promotion case brought successfully under the False Claims Act. The courts of New York State, for example, have refused to certify a class of plantiffs who took Neurontin for off-label use, finding that they had failed to state that they had any injury.
The University of California, San Francisco (UCSF) has archived and studied the documents made public by this case, which opens a window into the illegal promotion and marketing of pharmaceuticals. However, Pfizer maintains that the illegal activity originated in 1996, well before it acquired Parke-Davis (through its acquisition of Warner-Lambert) in 2000. Several lawsuits are underway after people who had been prescribed gabapentin for off-label treatment of bipolar disorder later attempted or committed suicide.
Various suppliers of gabapentin market it under a number of brand names, including Neurostil, Neurontin, Fanatrex, Gabarone, Gralise, Nupentin, Gabrion, Penral, Gabapin.
Gabapentin comes as:
- 100 mg, 300 mg, and 400 mg capsules
- 300 mg, 600 mg, and 800 mg tablets
- a 250 mg/5 mL oral (by mouth) solution.
Inactive ingredients in the capsules include lactose, cornstarch, and talc.
- The 100-mg capsule shell also contains: gelatin and titanium dioxide.
- The 300-mg capsule shell also contains: gelatin, titanium dioxide, and yellow iron oxide.
- The 400-mg capsule shell also contains: gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The imprinting ink contains FD&C Blue No. 2 and titanium dioxide.
Inactive ingredients in the tablets include poloxamer 407, copolyvidonum, cornstarch, magnesium stearate, hydroxypropyl cellulose, talc, candelilla wax, and purified water.
Inactive ingredients in the oral solution include glycerin, xylitol, purified water, and artificial flavor.
Parke-Davis developed a drug called pregabalin as a successor to gabapentin. Pregabalin was brought to market by Pfizer as Lyrica after the company acquired Warner-Lambert. Pregabalin is related in structure to gabapentin. Another new drug atagabalin has been trialed by Pfizer as a treatment for insomnia.
Gabapentin is also used for some animal treatments, but formulations (especially liquid forms) for human use may contain the sweetener Xylitol, which is toxic to dogs—so veterinary use of the human version requires caution.
- "Neurontin, Gralise (gabapentin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 6 April 2014.
- Goa, KL; Sorkin, EM (September 1993). "Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.". Drugs 46 (3): 409–27. doi:10.2165/00003495-199346030-00007. PMID 7693432.
- Attal N, Cruccu G, Baron R, et al. (September 2010). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". Eur. J. Neurol. 17 (9): 1113–e88. doi:10.1111/j.1468-1331.2010.02999.x. PMID 20402746.
- Stephen V. Sobel (5 November 2012). Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission. W. W. Norton. p. 124. ISBN 978-0-393-70857-8.
- D. John Reynolds; Jamie Coleman; Jeffrey Aronson (10 November 2011). Oxford Handbook of Practical Drug Therapy. Oxford University Press. p. 765. ISBN 978-0-19-956285-5.
- Vedula, SS; Bero L; Scherer RW; Dickersin K (November 2009). "Outcome reporting in industry-sponsored trials of gabapentin for off-label use". The New England Journal of Medicine 361 (20): 1963–71. doi:10.1056/NEJMsa0906126. PMID 19907043.
- "Gabapentin". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- Moore, RA; Wiffen, PJ; Derry, S; McQuay, HJ (Mar 16, 2011). "Gabapentin for chronic neuropathic pain and fibromyalgia in adults.". The Cochrane database of systematic reviews (3): CD007938. doi:10.1002/14651858.CD007938.pub2. PMID 21412914.
- Dauri, M; Faria, S; Gatti, A; Celidonio, L; Carpenedo, R; Sabato, AF (Aug 2009). "Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences.". Current drug targets 10 (8): 716–33. PMID 19702520.
- Bar Ad, V (September 2010). "Gabapentin for the treatment of cancer-related pain syndromes". Reviews on Recent Clinical Trials 5 (3): 174–8. doi:10.2174/157488710792007310. PMID 20482492.
- Phillips, TJ; Cherry CL; Cox S; Marshall SJ; Rice AS (2010-12-28). "Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials". In Pai, Nitika Pant. Plos One 5 (12): e14433. Bibcode:2010PLoSO...514433P. doi:10.1371/journal.pone.0014433. PMC 3010990. PMID 21203440.
- Wiffen, P; Collins S; McQuay H; Carroll D; Jadad A; Moore A (2005-07-20). "Anticonvulsant drugs for acute and chronic pain". In Wiffen, Philip J. Cochrane database of systematic reviews (Online) (3): CD001133. doi:10.1002/14651858.CD001133.pub2. PMID 16034857.
- Finnerup, NB; Sindrup SH; Jensen TS (September 2010). "The evidence for pharmacological treatment of neuropathic pain". Pain 150 (3): 573–81. doi:10.1016/j.pain.2010.06.019. PMID 20705215.
- Tran de, QH; Duong S; Bertini P; Finlayson RJ (February 2010). "Treatment of complex regional pain syndrome: a review of the evidence". Can J Anaesth 57 (57(2)): 149–66. doi:10.1007/s12630-009-9237-0. PMID 20054678.
- Linde, M; Mulleners, WM; Chronicle, EP; McCrory, DC (Jun 24, 2013). "Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults.". The Cochrane database of systematic reviews 6: CD010609. doi:10.1002/14651858.CD010609. PMID 23797675.
- Johannessen, SI; Ben-Menachem E (2006). "Management of focal-onset seizures: an update on drug treatment". Drugs 66 (13): 1701–25. doi:10.2165/00003495-200666130-00004. PMID 16978035.
- French, JA; Kanner AM; Bautista J; Abou-Khalil B; Browne T; Harden CL; Theodore WH; Bazil C; Stern J; Schachter SC; Bergen D; Hirtz D; Montouris GD; Nespeca M; Gidal B; Marks WJ; Turk WR; Fischer JH; Bourgeois B; Wilner A; Faught RE; Sachdeo RC; Beydoun A; Glauser TA (May 2004). "Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society". Epilepsia 45 (5): 401–9. doi:10.1111/j.0013-9580.2004.06204.x. PMID 15101821.
- Mula M, Pini S, Cassano GB (June 2007). "The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence". J Clin Psychopharmacol 27 (3): 263–72. doi:10.1097/jcp.0b013e318059361a. PMID 17502773.
- Alan F. Schatzberg; Jonathan O. Cole; Charles DeBattista (2010). Manual of Clinical Psychopharmacology. American Psychiatric Pub. pp. 344–345. ISBN 978-1-58562-377-8.
- Stephen M. Stahl; Bret A. Moore (13 February 2013). Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy. Routledge. p. 65. ISBN 978-1-136-44588-0.
- McLean, RJ; Gottlob I (August 2009). "The pharmacological treatment of nystagmus: a review". Expert opinion on pharmacotherapy 10 (11): 1805–16. doi:10.1517/14656560902978446. PMID 19601699.
- Strupp, M; Brandt T (July 2009). "Current treatment of vestibular, ocular motor disorders and nystagmus". Therapeutic Advances in Neurological Disorders 2 (4): 223–39. doi:10.1177/1756285609103120. PMC 3002631. PMID 21179531.
- Toulis, KA; Tzellos T; Kouvelas D; Goulis DG (February 2009). "Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis". Clinical therapeutics 31 (2): 221–35. doi:10.1016/j.clinthera.2009.02.006. PMID 19302896.
- Cheema, D; Coomarasamy A; El-Toukhy T (November 2007). "Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review". Archives of Gynecology and Obstetrics 276 (5): 463–9. doi:10.1007/s00404-007-0390-9. PMID 17593379.
- Rada, G; Capurro, D; Pantoja, T; Corbalán, J; Moreno, G; Letelier, LM; Vera, C (Sep 8, 2010). "Non-hormonal interventions for hot flushes in women with a history of breast cancer.". The Cochrane database of systematic reviews (9): CD004923. doi:10.1002/14651858.CD004923.pub2. PMID 20824841.
- Mack, Alicia (2003). "Examination of the evidence for off-label use of gabapentin". Journal of Managed Care Pharmacy 9 (6): 559–68. PMID 14664664.
- Muncie HL, Jr; Yasinian, Y; Oge', L (Nov 1, 2013). "Outpatient management of alcohol withdrawal syndrome.". American family physician 88 (9): 589–95. PMID 24364635.
- Sood, A; Ebbert JO; Schroeder DR; Croghan IT; Sood R; Vander Weg MW; Wong GY; Hays JT (February 2007). "Gabapentin for smoking cessation: a preliminary investigation of efficacy". Nicotine & Tobacco Research 9 (2): 291–8. doi:10.1080/14622200601080307. PMID 17365760.
- Sood, A; Ebbert JO; Wyatt KD; Croghan IT; Schroeder DR; Sood R; Hays JT (March 2010). "Gabapentin for smoking cessation". Nicotine & Tobacco Research 12 (3): 300–4. doi:10.1093/ntr/ntp195. PMC 2825098. PMID 20081039.
- Berger, TG; Steinhoff, M (June 2011). "Pruritus and renal failure.". Seminars in cutaneous medicine and surgery 30 (2): 99–100. doi:10.1016/j.sder.2011.04.005. PMID 21767770.
- Anand S (March 2013). "Gabapentin for pruritus in palliative care". American Journal of Hospice and Palliative Medicine 30 (2): 192–196. doi:10.1177/1049909112445464.
- Joseph F. Goldberg; Martin Harrow (1999). Bipolar Disorders: Clinical Course and Outcome. American Psychiatric Pub. p. 98. ISBN 978-0-88048-768-9.
- Freeman MP, Freeman SA, McElroy SL (February 2002). "The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues". J Affect Disord 68 (1): 1–23. PMID 11869778.
- Scott LJ (December 2012). "Gabapentin enacarbil: in patients with restless legs syndrome". CNS Drugs 26 (12): 1073–83. doi:10.1007/s40263-012-0020-3. PMID 23179641.
- Jack D. Edinger (2013). Insomnia, an Issue of Sleep Medicine Clinics. Elsevier Health Sciences. p. 339. ISBN 978-0-323-18872-2.
- Charles M. Morin; Colin A. Espie (2 February 2012). The Oxford Handbook of Sleep and Sleep Disorders. Oxford University Press. p. 544. ISBN 978-0-19-970442-2.
- Aazh, H; El Refaie, A; Humphriss, R (December 2011). "Gabapentin for tinnitus: a systematic review.". American journal of audiology 20 (2): 151–8. doi:10.1044/1059-0889(2011/10-0041). PMID 21940981.
- "Neurontin packaging insert" (pdf). U.S. Food and Drug Administration (FDA). 2009-05-01. Retrieved 2010-07-16.
- Jeffrey K Aronson (4 March 2014). Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Newnes. p. 137. ISBN 978-0-444-62636-3.
- American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.: DSM 5. bookpointUS. p. 482. GGKEY:LXJWL7ZHDAH.
- Lasso-de-la-Vega, MC; Zapater, P; Such, J; Perez-Mateo, M; Horga, JF (December 2001). "Gabapentin-associated hepatotoxicity". Am J Gastroenterol 96 (12): 3460–2. doi:10.1111/j.1572-0241.2001.05357.x. PMID 11774985.
- Dogukan, A; Aygen, B; Berilgen, MS; Dag, S; Bektas, S; Gunal, AI (April 2006). "Gabapentin-induced coma in a patient with renal failure". Hemodialysis International 10 (2): 168–9. doi:10.1111/j.1542-4758.2006.00089.x. PMID 16623669.
- Bookwalter, T; Gitlin, M (December 2005). "Gabapentin-induced neurologic toxicities". Pharmacotherapy 25 (12): 1817–9. doi:10.1592/phco.2005.25.12.1817. PMID 16305301.
- Gabapentin Official FDA information, side effects and uses
- "Suicidal Behavior and Ideation and Antiepileptic Drugs". U.S. Food and Drug Administration (FDA).
- Margaret Cronin Fisk; Jef Feeley; Cary O’Reilly (2009-07-24). "Pfizer Faces First Trial on Neurontin Suicide Claim (Update1)". Bloomberg. Retrieved 2010-07-16.
- R.C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 677–8. ISBN 978-0-9626523-7-0.
- Hendrich, J; Van Minh, AT; Heblich, F; Nieto-Rostro, M; Watschinger, K; Striessnig, J; Wratten, J; Davies, A et al. (March 2008). "Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin". Proceedings of the National Academy of Sciences of the United States of America 105 (9): 3628–33. Bibcode:2008PNAS..105.3628H. doi:10.1073/pnas.0708930105. PMC 2265195. PMID 18299583.
- Davies, A; Hendrich, J; Van Minh, AT; Wratten, J; Douglas, L; Dolphin, AC (May 2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels". Trends Pharmacol Sci 28 (5): 220–8. doi:10.1016/j.tips.2007.03.005. PMID 17403543.
- Eroglu, Ç; Allen, NJ; Susman, MW; O'Rourke, NA; Park, CY; Özkan, E; Chakraborty, C; Mulinyawe, SB et al. (October 2009). "The Gabapentin Receptor α2δ-1 is the Neuronal Thrombospondin Receptor Responsible for Excitatory CNS Synaptogenesis". Cell 139 (2): 380–92. doi:10.1016/j.cell.2009.09.025. PMC 2791798. PMID 19818485.
- Henney JE (August 2006). "Safeguarding patient welfare: who's in charge?". Annals of Internal Medicine 145 (4): 305–7. doi:10.7326/0003-4819-145-4-200608150-00013. PMID 16908923.
- "Warner–Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion" (Press release). Department of Justice. May 13, 2004. Retrieved December 2, 2009.
- Mathew, NT; Rapoport, A; Saper, J; Magnus, L; Klapper, J; Ramadan, N; Stacey, B; Tepper, S (February 2001). "Efficacy of Gabapentin in Migraine Prophylaxis". Headache: the Journal of Head and Face Pain 41 (2): 119–28. doi:10.1046/j.1526-4610.2001.111006119.x. PMID 11251695.
- Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003 Nov-Dec;9(6):559-68. PMID 14664664
- Pfizer Neurontin Label, Revised: 5/2013 Retrieved 9 August 2014
- Reinares M, Rosa AR, Franco C, et al. (March 2013). "A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression". Int. J. Neuropsychopharmacol. 16 (2): 485–96. doi:10.1017/S1461145712000491. PMID 22575611.
- Berkrot, Bill (2010-03-25). "US jury's Neurontin ruling to cost Pfizer $141 mln". Reuters.
- "Pfizer faces $142M in damages for drug fraud". Business Week. 2010-03-25. Retrieved 13 January 2012.
- Bob Van Voris; Janelle Lawrence (2010-03-26). "Pfizer Told to Pay $142.1 Million for Neurontin Marketing Fraud". Bloomberg News. Retrieved 13 January 2012.
- Jon Kamp (2010-03-25). "Jury Rules Against Pfizer in Marketing Case". The Wall Street Journal. Retrieved 13 January 2012.
- Tansey, Bernadette (2004-05-14). "Huge penalty in drug fraud, Pfizer settles felony case in Neurontin off-label promotion". San Francisco Chronicle. p. C-1.
- "Baron v Pfizer, Inc." 2007 NY Slip Op 05813 [42 AD3d 627]. July 5, 2007.
- Drug Industry Document Archive
- Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents – Steinman et al. 145 (4): 284 – Annals of Internal Medicine
- Gabapentin Information and Uses - rxwiki.com
- Baillie, JK; Power, I (January 2006). "The mechanism of action of gabapentin in neuropathic pain". Curr Opin Investig Drugs 7 (1): 33–9. ISSN 1472-4472. PMID 16425669.
- Jensen B, Regier LD, editors. RxFiles : Drug comparison charts. 7th ed. Saskatoon, SK: RxFiles, 2010; p.78
- Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607.
- Barbara Forney. "Gabapentin for Veterinary Use".
- DrugBank: gabapentin
- Gabapentin information from MedlinePlus
- "Gabapentin" PubMed Health. National Center for Biotechnology Information (NCBI)
- "Suicidal Behavior and Ideation and Antiepileptic Drugs" U.S. Food and Drug Administration (FDA)
- Neurontin collected news and commentary at The New York Times
- "Gabapentin" Drug Information Portal. U.S. National Library of Medicine.